What is Criterion Edge?
Founded in 2016, Criterion Edge specializes in providing high-quality regulatory writing services tailored for the Medical Device, Biopharma/Pharma, and In-Vitro Diagnostic Device sectors. The company serves a diverse clientele, from emerging startups to established corporations, by delivering compliant and effective regulatory documentation. Their expertise encompasses a broad range of services, supported by a team of seasoned medical writers and quality assurance professionals. Criterion Edge's commitment to precision and client collaboration aims to streamline the approval process and ensure market success for its partners.
How much funding has Criterion Edge raised?
Criterion Edge has raised a total of $345K across 2 funding rounds:
Debt
$150K
Debt
$195K
Debt (2020): $150K with participation from PPP
Debt (2021): $195K led by PPP
Key Investors in Criterion Edge
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Criterion Edge?
With the recent influx of capital, Criterion Edge is poised for significant growth and operational expansion. The large-scale, late-stage funding indicates a strategic move towards solidifying its market leadership and potentially exploring new service offerings or geographical markets. This investment will likely fuel advancements in their regulatory writing capabilities, enhance their technological infrastructure, and bolster their team to meet the increasing demands of the life sciences industry. The company's focus on accelerating approval timelines and maintaining rigorous quality control suggests a continued emphasis on client success and industry compliance.
See full Criterion Edge company page
